- Home
- PKBK vs NGEN Comparison
PKBK vs NGEN Comparison
Compare PKBK & NGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | PKBK | NGEN |
|---|---|---|
| Founded | 1999 | 2017 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 330.0M | 317.6M |
| IPO Year | 2005 | N/A |
Fundamental Metrics
Financial Performance| Metric | PKBK | NGEN |
|---|---|---|
| Price | $28.09 | $4.19 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 87.8K | ★ 114.9K |
| Earning Date | 04-23-2026 | 01-01-0001 |
| Dividend Yield | ★ 2.58% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.23 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.51 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.94 | $3.73 |
| 52 Week High | $29.50 | $5.93 |
Technical Indicators
Market Signals| Indicator | PKBK | NGEN |
|---|---|---|
| Relative Strength Index (RSI) | 53.47 | 39.96 |
| Support Level | $26.55 | $3.73 |
| Resistance Level | $28.22 | $4.50 |
| Average True Range (ATR) | 0.76 | 0.25 |
| MACD | -0.17 | 0.05 |
| Stochastic Oscillator | 31.93 | 50.00 |
Price Performance
Historical ComparisonAbout PKBK Parke Bancorp Inc.
Parke Bancorp Inc operates as a commercial bank providing personal and financial services to individuals and small to mid-sized businesses in various states of the USA. The bank offers services such as loan products, deposit services, and other financial products through its retail branches and other channels to its customers. Its lending businesses are commercial real estate lending, residential real estate lending, and construction lending among others. The Company operates one reportable segment of business, community banking.
About NGEN NervGen Pharma Corp. Common stock
NervGen Pharma Corp is a clinical-stage biotech company. The company's principal business activity is the discovery, development, and commercialization of pharmaceutical treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. The company's initial target indication is spinal cord injury. The company's pipeline products include NVG-291 and NVG-300.